Literature DB >> 11145166

Purification of human ceruloplasmin as a by-product of C1-inhibitor.

F Kouoh Elombo1, M Radosevich, M Poulle, J Descamps, S Chtourou, T Burnouf, J P Catteau, J L Bernier, N Cotelle.   

Abstract

Human ceruloplasmin (Cp) has been purified from cryoprecipitate-poor plasma as a by-product of the C1-inhibitor production chain. Highly purified Cp was obtained by subsequent ion-exchange chromatography on sulfate-Fractogel EMD and TMAE-Fractogel EMD. Treatments for viral safety included application of the solvent-detergent method and two nanofiltration steps using 35- and 15-nm pore size filters at the end of the process. Overall antigen yield was 95 (+/-5) %. Purified human ceruloplasmin was studied by electron spin resonance (ESR) to characterize its different types of copper complexes and to check its antioxidant properties. We distinguished three types of complexes: one type-2 Cu(II) with g// = 2.25 and A// = 180 G and two type-I Cu(II) exhibiting different narrow hyperfine splitting (A// = 72 G and A// = 90 G) with close g// (2.20 and 2.21). Purified Cp has a specific activity of 24.5+/-0.2 mU/mg of proteins. This process provides a method for Cp purification that could be easily integrated into modern plasma fractionation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11145166     DOI: 10.1248/bpb.23.1406

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  2 in total

1.  The influence of radiotherapy on ceruloplasmin and transferrin in whole blood of breast cancer patients.

Authors:  Ryszard Krzyminiewski; Bernadeta Dobosz; Tomasz Kubiak
Journal:  Radiat Environ Biophys       Date:  2017-08-28       Impact factor: 1.925

2.  Ceruloplasmin in flatland: the relationship between enzyme catalytic activity and surface hydrophilicity.

Authors:  Agata Kowalczyk; Cong Yu; Anna M Nowicka
Journal:  RSC Adv       Date:  2022-09-06       Impact factor: 4.036

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.